Teleflex Inc Stock Price, News & Analysis

Teleflex (NYSE: TFX) has secured a contract with Vizient, effective August 1, 2022, for supplying Central Venous Access products. This deal allows Vizient's members, which include over 50% of U.S. acute care providers, to access pre-negotiated pricing on Teleflex's products. Teleflex, a market leader in Central Venous Catheters, aims to enhance patient outcomes and minimize complications. The agreement includes Arrowg+ard Blue Plus® CVCs, which significantly reduce central line-associated infections, showcasing Teleflex's commitment to innovation in vascular access.

Teleflex Incorporated (NYSE: TFX) published its 2021 Global Impact Report, outlining achievements in its Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative and Sustainability Accounting Standards Board standards.

Key highlights include commitments to reduce energy, water use, and waste, along with the installation of solar panels generating over 5 GWh of renewable electricity. The report emphasizes diversity, equity, and inclusion efforts and investments in tracking environmental metrics, showcasing the company's dedication to ethical governance, sustainability, and community impact.

Teleflex Incorporated (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share, payable on September 15, 2022. Shareholders of record as of August 15, 2022 will receive this dividend. The company focuses on medical technologies aimed at enhancing health and quality of life, with a diverse product portfolio across various medical fields. For more information, visit teleflex.com.

Teleflex reported second quarter 2022 revenues of $704.5 million, a 1.3% decline year-over-year, but a 2.3% increase on a constant currency basis. GAAP diluted EPS rose to $2.23, up from $1.76 in the previous year. However, the company reduced its 2022 revenue growth guidance to (0.45% to 0.55%) and GAAP EPS guidance to $8.04 to $8.44. The decline was attributed mainly to challenges in the Interventional Urology segment and foreign currency impacts. Despite this, Teleflex remains focused on long-term growth strategies in its high-growth portfolio.

Teleflex Incorporated (NYSE: TFX) is participating in the Pocono Raceway NASCAR event from July 22-24, 2022, to raise awareness about benign prostatic hyperplasia (BPH). BPH affects over 14 million men, causing symptoms like urinary frequency and urgency. The company emphasizes the importance of routine screenings, especially after many delayed medical care during the COVID-19 pandemic. At the event, Teleflex will feature the UroLift® System, a minimally invasive treatment for BPH, and host patient ambassadors to share personal experiences.

Teleflex Incorporated (NYSE: TFX) is set to host a conference call on July 28, 2022, at 8:00 a.m. ET to discuss its second quarter financial results and provide an operational update. Participants can pre-register using a provided link or access the live audio webcast on the company’s website. An audio replay will be available after the call. Teleflex is a global provider of medical technologies aimed at improving health outcomes, with products in various medical fields, including vascular access and anesthesia.

Teleflex announced promising findings at the 37th Annual European Association of Urology Congress regarding its UroLift System for treating benign prostatic hyperplasia (BPH). Key results showed that 79% of over 300 subjects reported a reduction in their IPSS symptom severity 12 months post-treatment. Furthermore, symptom improvement was independent of prostate size or shape. The study also highlighted that patients treated with UroLift required significantly fewer prescriptions post-surgery compared to those undergoing more invasive procedures.

Teleflex Incorporated (NYSE: TFX) announced the first patient enrolled in the MANTA Ultra Study, aimed at assessing the safety of the MANTA® Vascular Closure Device using ultrasound guidance during elective TAVR procedures. This prospective study will involve up to 150 patients across 15 sites in the US and Canada, focusing on reducing access site complications associated with large bore procedures. Key endpoints include major and minor vascular complications within 30 days, along with various effectiveness measures. The study could enhance procedural flexibility for surgeons.

Teleflex Incorporated (NYSE: TFX) announced the launch of its Arrow Pressure Injectable Midline Catheter in Europe, the Middle East, and Africa. This new catheter, featuring brightly colored hubs to enhance clinician identification and minimize infusion errors, is available in 1-lumen and 2-lumen configurations. Key features include a TAPERFREE design to reduce venous stasis and procedural efficiency enhancements. The device allows for pressure injection up to 5 mL/second, improving patient care and reducing delays in diagnostics.